<DOC>
	<DOC>NCT00189631</DOC>
	<brief_summary>To compare maintenance therapy to observation in metastatic breast cancer patients responding (or stabilized) after 1st-line chemotherapy. Main endpoint is disease-free survival. Secondary endpoints are overall survival and tolerance. A total of 200 patients will be included.</brief_summary>
	<brief_title>UFT/LV Maintenance Vs Observation in Metastatic Breast Cancer Responsive to Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>metastatic breast cancer objective response or stabilisation after 6 to 8 cycle of a first line chemotherapy time period between the end of chemotherapy and randomization &lt; 4 weeks age over 18 years Performance status (OMS) &lt; 2. Life expectancy &gt; 3 months Biological criteria before randomization: Neutrophiles &gt; 1.5 x 109 G/L; Pl. &gt; 100 x 109 G/L; Hb &gt; 10 g/dl; Creatininemia &lt; 1,5 UNL; Bili. &lt; 2 UNL; Transaminases &lt; 2,5 UNL; Alcalines Phosphatases &lt; 2,5 UNL Signed written informed consent Metastatic breast cancer having received more than one chemotherapy line. Tumor progression under chemotherapy Free interval between primary tumor and metastases &gt; 5 years, with estrogen receptors and without visceral metastases Free interval between primary tumor and metastases &lt; 18 months after adjuvant chemotherapy if first lime chemotherapy only led to a tumor stabilization Concomitant hormonotherapy Other cancer Symptomatic brain metastases Any uncontrolled severe disease except breast cancer (especially cardiac failure with LVEF &lt; 50% or coronary insufficiency Psychiatric disorder Other concomitant trial Male patient Pregnancy and breastfeeding (effective contraception is mandatory in the case of women of childbearing potential) History of high dose chemotherapy with bone marrow transplantation</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>